EyePoint updates on DURAVYU Phase 3 wet AMD trials enrollment ahead of schedule, Phase 2 DME data expected 1Q 2025

EyePoint, Inc.

Phase 3 LUGANO trial for DURAVYU in wet AMD one-third enrolled; LUCIA trial tracking ahead of schedule; full enrollment target 2H 2025.
Full data from Phase 2 VERONA trial of DURAVYU in DME expected 1Q 2025; interim data showed BCVA gain +8.9 letters and CST improvement.
Cash and investments ~$370M at Dec 31, 2024; cash runway into 2027 beyond Phase 3 wet AMD topline data expected in 2026.
Appointed retina specialist Reginald J. Sanders, M.D., FASRS to Board of Directors.
Opened new 40,000+ sq ft cGMP manufacturing facility in Northbridge, MA to support commercial readiness.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.